Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2003-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/J.1365-2125.2003.01888.XPMID 12968984PMCID PMC1884361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacodynamic Studies with Cilazapril and a Combination of Cilazapril and Propranolol

  2012cited by this paper
• A Review of Vasopeptidase Inhibitors: A New Modality in the Treatment of Hypertension and Chronic Heart Failure

  2002cited by this paper
• Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With Systolic Hypertension: Results of the Conduit Hemodynamics of Omapatrilat International Research Study

  2002cited by this paper
• Omapatrilat--the story of Overture and Octave.

  2002cited by this paper
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

  2002cited by this paper
• Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics.

  2001cited by this paper
• Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients

  2001cited by this paper
• Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers.

  2001cited by this paper
• In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat

  2001cited by this paper
• Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?

  2001cited by this paper
• Omapatrilat in patients with hepatic cirrhosis

  2001cited by this paper
• Omapatrilat: Neurohormonal and Pharmacodynamic Profile When Administered with Furosemide

  2001cited by this paper
• Atrial Natriuretic Peptide: Regulator of Chronic Arterial Blood Pressure.

  2000cited by this paper
• Pharmacodynamic effects of dual neutral endopeptidase–angiotensin‐converting enzyme inhibition versus angiotensin‐converting enzyme inhibition in humans

  1999cited by this paper
• Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

  1999cited by this paper
• Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat.

  1999cited by this paper
• Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension

  1999cited by this paper
• Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

  1999cited by this paper
• Vasopeptidase inhibition: a new concept in blood pressure management.

  1999cited by this paper
• Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.

  1998cited by this paper
• Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers.

  1998cited by this paper
• Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels.

  1998cited by this paper
• Effects of omapatrilat in low, normal, and high renin experimental hypertension.

  1998cited by this paper
• Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.

  1998cited by this paper
• Quantitative determination of BMS186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct.

  1997cited by this paper
• Atrial natriuretic peptide‐C receptor and membrane signalling in hypertension

  1997cited by this paper
• Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men.

  1995cited by this paper
• Kinins and endothelial control of vascular smooth muscle.

  1995cited by this paper
• Kinins and Endothelial Control of Vascular Smooth Muscle

  1995cited by this paper
• Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.

  1994cited by this paper
• Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.

  1994cited by this paper
• Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.

  1994cited by this paper
• Acute renal effects of neutral endopeptidase inhibition in humans.

  1994cited by this paper
• Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

  1993cited by this paper
• Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition.

  1992cited by this paper
• Combination of high-performance liquid chromatography and radioimmunoassay for the measurement of urodilatin and alpha-hANP in the urine of healthy males.

  1991cited by this paper
• Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

  1991cited by this paper
• Combination of high-performance liquid chromatography and radioimmunoassay for the measurement of urodilatin and α-hANP in the urine of healthy males

  1991cited by this paper
• Downregulation of glomerular and vascular atrial natriuretic factor receptor subtypes by angiotensin II.

  1991cited by this paper
• Dietary Sodium and Inhibition of Neutral Endopeptidase 24.11 in Essential Hypertension

  1991cited by this paper
• Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.

  1990cited by this paper
• Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide.

  1989cited by this paper
• Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1

  1989cited by this paper
• Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man.

  1988cited by this paper
• Isolation and structural analysis of “Urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine

  1988cited by this paper
• Urodilatin (CDD/ANP‐95‐126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (α‐hANP/CDD‐99‐126)

  1988cited by this paper
• Effect of low dose infusion of atrial natriuretic peptide on renal function in man.

  1988cited by this paper
• Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

  1984cited by this paper
• Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides.

  1983cited by this paper
• SOME PROBLEMS IN INTERVAL ESTIMATION

  1954cited by this paper

• Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome

  2025cites this paper
• Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management

  2024cites this paper
• Green synthetic approaches for medium ring–sized heterocycles of biological and pharmaceutical interest

  2021cites this paper
• TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

  2020cites this paper
• TCRM_A_234772 715..726

  2020cites this paper
• Microwave-mediated Synthesis of Medium Ring-sized Heterocyclic Compounds

  2020cites this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects

  2020cites this paper
• Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data

  2020cites this paper
• Sacubitril/Valsartan: A Game Changer in the Treatment for Heart Failure HFrEF, PARADIGM-HF, angiotensin receptor neprilysin inhibitor (ARNI)

  2019cites this paper
• Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease

  2019cites this paper
• Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor

  2018cites this paper
• Treatments for Heart Failure

  2017cites this paper
• Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

  2016cites this paper
• Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date

  2016cites this paper
• Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

  2015cites this paper
• Dual-Acting Angiotensin Receptor–Neprilysin Inhibition

  2011cites this paper
• Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

  2010cites this paper
• Characterisation of the pharmacological actions in humans of multiple vasoactive enzyme inhibitors with therapeutic potential in heart failure

  2007cites this paper
• Chapter 71 – Vasopeptidase Inhibitors

  2005cites this paper
• Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive Rats

  2005cites this paper
• How First‐Time‐in‐Human Studies Are Being Performed: A Survey of Phase I Dose‐Escalation Trials in Healthy Volunteers Published Between 1995 and 2004

  2005cites this paper
• Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.

  2005cites this paper
• Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.

  2004cites this paper